This company listing is no longer active
Merrimack Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Merrimack Pharmaceuticals has a total shareholder equity of $221.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $244.3M and $22.7M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$244.11m |
| Equity | US$221.65m |
| Total liabilities | US$22.67m |
| Total assets | US$244.32m |
Recent financial health updates
We're Not Worried About Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash Burn
Feb 14
Companies Like Merrimack Pharmaceuticals (NASDAQ:MACK) Are In A Position To Invest In Growth
Sep 23Here's Why We're Not At All Concerned With Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash Burn Situation
Mar 19We're Interested To See How Merrimack Pharmaceuticals (NASDAQ:MACK) Uses Its Cash Hoard To Grow
May 19Recent updates
We're Not Worried About Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash Burn
Feb 14Companies Like Merrimack Pharmaceuticals (NASDAQ:MACK) Are In A Position To Invest In Growth
Sep 23Merrimack Pharmaceuticals GAAP EPS of -$0.04
Aug 04Here's Why We're Not At All Concerned With Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash Burn Situation
Mar 19We're Interested To See How Merrimack Pharmaceuticals (NASDAQ:MACK) Uses Its Cash Hoard To Grow
May 19Are Insiders Selling Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Stock?
Feb 22Merrimack Pharmaceuticals (NASDAQ:MACK) Is In A Strong Position To Grow Its Business
Jan 01Financial Position Analysis
Short Term Liabilities: MACK's short term assets ($244.3M) exceed its short term liabilities ($22.7M).
Long Term Liabilities: MACK has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: MACK is debt free.
Reducing Debt: MACK has no debt compared to 5 years ago when its debt to equity ratio was 30.6%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MACK has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: MACK has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 66.7% each year
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/05/21 01:49 |
| End of Day Share Price | 2024/05/17 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Merrimack Pharmaceuticals, Inc. is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Ulz | Baird |
| Rachel McMinn | BofA Global Research |
| Jonathan Aschoff | Brean Capital |